Cover Image
市場調查報告書

全球癌症診斷市場分析:各類型 (臨床檢驗,遺傳基因檢驗,影像診斷,內視鏡檢驗,純粹研),各用途 (乳癌,肺癌,肝癌,子宮頸癌,大腸癌,皮膚癌,血液癌症,腎癌症,前列腺癌,卵巢癌,胰臟癌症),市場區隔預測

Cancer Diagnostics Market Analysis By Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy), By Application (Breast, Lung, Liver, Cervical, Colorectal, Skin), By Region, And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 408926
出版日期 內容資訊 英文 90 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球癌症診斷市場分析:各類型 (臨床檢驗,遺傳基因檢驗,影像診斷,內視鏡檢驗,純粹研),各用途 (乳癌,肺癌,肝癌,子宮頸癌,大腸癌,皮膚癌,血液癌症,腎癌症,前列腺癌,卵巢癌,胰臟癌症),市場區隔預測 Cancer Diagnostics Market Analysis By Type (Laboratory Tests, Genetic Tests, Imaging, Endoscopy), By Application (Breast, Lung, Liver, Cervical, Colorectal, Skin), By Region, And Segment Forecasts, 2014 - 2025
出版日期: 2017年03月15日 內容資訊: 英文 90 Pages
簡介

本報告提供全球癌症診斷市場相關調查分析,提供您市場概要,市場趨勢,市場動態等相關考察,並依種類,用途,地區別彙整市場綜合性分析。

第1章 調查方法

第2章 摘要整理

第3章 癌症診斷市場變數,趨勢,範圍

  • 市場區隔和範圍
  • 推動市場的要素分析
  • 市場抑制因素分析
  • 癌症診斷:SWOT分析:因素別 (政策/法律,經濟,技術)
  • 波特的五力分析

第4章 癌症診斷市場:篩檢類別:評估,趨勢分析

  • 癌症診斷市場:篩檢種類趨勢分析
  • 臨床檢驗
  • 遺傳基因檢驗
  • 影像診斷
  • 內視鏡檢驗
  • 純粹研
  • 其他 (鋇灌腸檢驗)

第5章 癌症診斷市場:各用途:評估,趨勢分析

  • 癌症診斷市場:用途趨勢分析
  • 乳癌
  • 大腸癌
  • 子宮頸癌
  • 肺癌
  • 前列腺癌
  • 皮膚癌
  • 血液癌症
  • 腎癌症
  • 肝癌
  • 胰臟癌症
  • 卵巢癌
  • 其他

第6章 癌症診斷市場:各地區:評估,趨勢分析

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東/非洲

第7章 競爭情形

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GVR-1-68038-213-6

The global cancer diagnostics market is expected to reach USD 232.7 billion by 2025, according to a new report by Grand View Research, Inc. Continual introduction of innovative products coupled with increasing need for early diagnosis of the disease is the prime factor driving the market growth. In addition, rapid growth of the sector is attributed to the penetration of technologically advanced laboratory systems that have improved oncological screening in yielding accurate outcomes. Rising incidence of cancer is triggering the demand for these screening tests and imaging modalities that are used for monitoring disease progression.

Collaborative and independent initiatives led by governments and companies are striving to raise cognizance about the benefits of early diagnosis of the disease. In addition, cancer research organizations along with public and private entities are investing heavily on research projects to launch advanced diagnostic tools in the market, which are capable of diagnosing the disease way before the symptoms appear.

Furthermore, giant players are collaborating with governments and other agencies to enhance patient accessibility of their products. For instance, Illumina, Inc. launched a new venture named GRAIL with investors, Jeff Bezos and Bill Gates, with an investment of more than $100 million. GRAIL is mainly focused on blood-based oncological screening for timely diagnosis of the most common tumor types through simple laboratory tests.

Further Key Findings from the Study Suggest:

  • Rapid adoption of technology and escalating need for early diagnosis is augmenting the growth of the imaging systems space. Thus, the segment is expected to grow at the fastest CAGR at over 8.0% during the forecast period.
  • The breast cancer segment, among other application segments, accounted for the largest share due to the high incidence rate of breast cancer triggering the need for its early diagnosis.
  • In 2016, North America dominated the global space with the largest revenue share of more than 41%. Focused research efforts in oncology for the development of early tumor detection tools coupled with grants from government healthcare agencies are contributing to a strong medical ecosystem to fight cancer in this region.
  • Asia Pacific is expected to emerge as the fastest growing region during the forecast period. The growing patient pool in India, China, and Japan; due to the support in diagnostic process at comparatively lower prices; and a favorable regulatory framework are some of the factors boosting the market growth in this region.
  • Major players competing in this market include GE Healthcare; Abbott; Hoffmann-La Roche Ltd and Siemens Healthcare GmbH. Other prominent players operating in the market include but are not limited to Becton Dickinson & Company; Illumina, Inc.; Koninklijke Philips N.V.; .and Hologic, Inc.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information procurement
  • 1.2 Data Analysis
  • 1.3 Approaches for market estimation
    • 1.3.1 Approach 1: Demand Analysis & Bottom up Approach
    • 1.3.2 Approach 2: Top down market estimation
    • 1.3.3 Approach 3: Commodity flow and bottom up market estimation
    • 1.3.4 Approach 4: KoL perspective based market sizing

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Cancer Diagnostics Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
  • 3.2 Market Driver Analysis
    • 3.2.1 Rising prevalence of cancer cases
    • 3.2.2 Technological advancement
    • 3.2.3 Initiatives undertaken by government
    • 3.2.4 Reimbursement coverage
  • 3.3 Market Restraints Analysis
    • 3.3.1 Lack of sensitivity and specificity
    • 3.3.2 Risk of high radiation exposure used in different treatments
    • 3.3.3 Cost of diagnosis
  • 3.4 Penetration & growth prospect mapping
  • 3.5 Cancer Diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.6 Industry Analysis - Porter's

Chapter 4 Cancer Diagnostics: Screening Type Estimates & Trend Analysis

  • 4.1 Cancer Diagnostics Market: Screening Type movement analysis
    • 4.1.1. Laboratory Tests
      • 4.1.1.1 Laboratory Tests Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 4.1.2 Genetic Tests
      • 4.1.2.1 Genetic Tests Market Estimates and Forecasts, 2014 - 2025 (USD Billion))
    • 4.1.3 Imaging
      • 4.1.3.1 Imaging Market Estimates and Forecasts, 2014 - 2025 (USD Billion))
    • 4.1.4 Endoscopy
      • 4.1.4.1 Endoscopy Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 4.1.5 Biopsy
      • 4.1.5.1 Biopsy Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 4.1.6 Others ( Barium Enema)
      • 4.1.6.1 Others Market Estimates and Forecasts, 2014 - 2025 (USD Billion)

Chapter 5 Cancer Diagnostics: Application Estimates & Trend Analysis

  • 5.1 Cancer Diagnostics Market: Application movement analysis
    • 5.1.1 Breast Cancer
      • 5.1.1.1 Breast Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.2 Colorectal Cancer
      • 5.1.2.1 Colorectal Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.3 Cervical Cancer
      • 5.1.3.1 Cervical Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.4 Lung Cancer
      • 5.1.4.1 Lung Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.5 Prostate cancer
      • 5.1.5.1 Prostate Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.6 Skin Cancer
      • 5.1.6.1 Skin Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.7 Blood Cancer
      • 5.1.7.1 Blood Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.8 Kidney Cancer
      • 5.1.8.1 Kidney Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.9 Liver Cancer
      • 5.1.9.1 Liver Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.10 Pancreatic Cancer
      • 5.1.10.1 Pancreatic Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.11 Ovarian Cancer
      • 5.1.11.1 Ovarian Cancer Market Estimates and Forecasts, 2014 - 2025 (USD Billion)
    • 5.1.12 Others
      • 5.1.12.1 Others Market Estimates and Forecasts, 2014 - 2025 (USD Billion)

Chapter 6 Cancer Diagnostics: Regional Estimates &Trend Analysis, by Screening Type & Application Type

  • 6.1 Cancer Diagnostics Market Share By Region, 2015 & 2025
  • 6.2 North America
    • 6.2.1 North America Cancer Diagnostics Market, 2014 - 2025 (USD Billion)
    • 6.2.2 U.S.
      • 6.2.2.1 Market Estimates & Forecast, By Screening Type 2014 - 2025 (USD Billion)
      • 6.2.2.2 Market Estimates & Forecast, By Application 2014 - 2025 (USD Billion)
    • 6.2.3 Canada
      • 6.2.3.1 Market Estimates & Forecast, By Screening Type 2014 - 2025 (USD Billion)
      • 6.2.3.2 Market Estimates & Forecast, By Application 2014 - 2025 (USD Billion)
  • 6.3 Europe
    • 6.3.1 Europe Cancer Diagnostics Market, 2014 - 2025 (USD Billion)
    • 6.3.2 UK
      • 6.3.2.1 Market Estimates & Forecast, By Screening Type 2014 - 2025 (USD Billion)
      • 6.3.2.2 Market Estimates & Forecast, By Application 2014 - 2025 (USD Billion)
    • 6.3.3 Germany
      • 6.3.3.1 Market Estimates & Forecast, By Screening Type 2014 - 2025 (USD Billion)
      • 6.3.3.2 Market Estimates & Forecast, By Application 2014 - 2025 (USD Billion)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific Cancer Diagnostics Market, 2014 - 2025 (USD Billion)
    • 6.4.2 Japan
      • 6.3.2.1 Market Estimates & Forecast, By Screening Type 2014 - 2025 (USD Billion)
      • 6.3.2.2 Market Estimates & Forecast, By Application 2014 - 2025 (USD Billion)
    • 6.4.3 China
      • 6.3.3.1 Market Estimates & Forecast, By Screening Type 2014 - 2025 (USD Billion)
      • 6.3.3.2 Market Estimates & Forecast, By Application 2014 - 2025 (USD Billion)
  • 6.5 Latin America
    • 6.5.1 Latin America Cancer Diagnostics Market, 2014 - 2025 (USD Billion)
    • 6.5.2 Brazil
      • 6.5.2.1 Market Estimates & forecast, By Screening Type 2014 - 2025 (USD Billion)
      • 6.5.2.2 Market Estimates & Forecast, By Application 2014 - 2025 (USD Billion)
    • 6.5.3 Mexico
      • 6.5.3.1 Market Estimates & Forecast, By Screening Type 2014 - 2025 (USD Billion)
      • 6.5.3.2 Market Estimates & Forecast, By Application 2014 - 2025 (USD Billion)
  • 6.6 MEA
    • 6.6.1 MEA Cancer Diagnostics Market, 2014 - 2025 (USD Billion)
    • 6.6.2 South Africa
      • 6.6.2.1 Market Estimates & Forecast, By Screening Type 2014 - 2025 (USD Billion)
      • 6.6.2.2 Market Estimates & Forecast, By Application 2014 - 2025 (USD Billion)

Chapter 7 Competitive Landscape

  • 7.1 Abbott
    • 7.1.1 Company Overview
    • 7.1.2 Financial Performance
    • 7.1.3 Product Benchmarking
    • 7.1.4 Strategic Initiatives
  • 7.2 Qiagen
    • 7.2.1 Company Overview
    • 7.2.2 Financial Performance
    • 7.2.3 Product Benchmarking
    • 7.2.4 Strategic Initiatives
  • 7.3 F. Hoffmann-La Roche Ltd.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Performance
    • 7.3.3 Product Benchmarking
    • 7.3.4 Strategic Initiatives
  • 7.4 Siemens Healthcare GmbH
    • 7.4.1 Company Overview
    • 7.4.2 Financial Performance
    • 7.4.3 Product Benchmarking
    • 7.4.4 Strategic Initiatives
  • 7.5 Thermo Fisher Scientific, Inc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Performance
    • 7.5.3 Product Benchmarking
    • 7.5.4 Strategic Initiatives
  • 7.6 GE Healthcare
    • 7.6.1 Company Overview
    • 7.6.2 Financial Performance
    • 7.6.3 Product Benchmarking
    • 7.6.4 Strategic Initiatives
  • 7.7 Hologic,Inc.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Performance
    • 7.7.3 Product Benchmarking
    • 7.7.4 Strategic Initiatives
  • 7.8 Becton, Dickinson and Company
    • 7.8.1 Company Overview
    • 7.8.2 Financial Performance
    • 7.8.3 Product Benchmarking
    • 7.8.4 Strategic Initiatives
  • 7.9 Koninklijke Philips N.V.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Performance
    • 7.9.3 Product Benchmarking
    • 7.9.4 Strategic Initiatives
  • 7.10 Illumina, Inc.
    • 7.10.1 Company Overview
    • 7.10.2 Financial Performance
    • 7.10.3 Product Benchmarking
    • 7.10.4 Strategic Initiatives

List of Tables

  • TABLE 1 North America Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 2 North America Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 3 U.S. Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 4 U.S. Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 5 Canada Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 6 Canada Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 7 Europe Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 8 Europe Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 9 UK Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 10 UK Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 11 Germany Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 12 Germany Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 13 Asia Pacific Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 14 Asia Pacific Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 15 Japan Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USDBillion);
  • TABLE 16 Japan Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 17 China Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 18 China Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 19 Latin America Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 20 Latin America Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 21 Brazil Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USDBillion)
  • TABLE 22 Brazil Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 23 Mexico Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 24 Mexico Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 25 MEA Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 26 MEA Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)
  • TABLE 27 South Africa Cancer Diagnostics Market, By Screening type, 2014 - 2025 (USD Billion)
  • TABLE 28 South Africa Cancer Diagnostics, By Application, 2014 - 2025 (USD Billion)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market driver relevance analysis (Current & future impact)
  • FIG. 12 Penetration & Growth prospect mapping
  • FIG. 13 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 14 Porter's Five Forces Analysis
  • FIG. 15 Cancer Diagnostics Market product outlook key takeaways
  • FIG. 16 Cancer Diagnostics: Screening Type movement analysis
  • FIG. 17 Laboratory Tests Market, 2014 - 2025 (USDBillion)
  • FIG. 18 Genetic Tests Market, 2014 - 2025 (USD Billion)
  • FIG. 19 Imaging Market, 2014 - 2025 (USD Billion)
  • FIG. 20 Endoscopy Market, 2014 - 2025 (USD Billion)
  • FIG. 21 BiopsyMarket, 2014 - 2025 (USD Billion
  • FIG. 22 Others Market, 2014 - 2025 (USDBillion)
  • FIG. 23 Cancer Diagnostics market Application outlook key takeaways
  • FIG. 24 Cancer Diagnostics : Application movement analysis
  • FIG. 25 Breast Cancer Market, 2014 - 2025 (USD Billion)
  • FIG. 26 Colorectal Cancer Market, 2014 - 2025 (USD Billion)
  • FIG. 27 Cervical Cancer Market, 2014 - 2025 (USD Billion)
  • FIG. 28 Lung Cancer Market, 2014 - 2025 (USD Billion)
  • FIG. 29 Prostate Cancer Market, 2014 - 2025 (USD Billion)
  • FIG. 30 Skin Cancer Market, 2014 - 2025 (USDBillion)
  • FIG. 31 Blood Cancer Market, 2014 - 2025 (USDBillion)
  • FIG. 32 Kidney Cancer Market, 2014 - 2025 (USD Billion)
  • FIG. 33 Liver Cancer Market, 2014 - 2025 (USD Billion)
  • FIG. 34 Pancreatic Cancer Market, 2014 - 2025 (USD Billion)
  • FIG. 35 Ovarian Cancer Market, 2014 - 2025 (USD Billion)
  • FIG. 36 Others Market, 2014 - 2025 (USD Billion)
  • FIG. 37 Regional market place: Key takeaways
  • FIG. 38 Strategy framework
  • FIG. 39 Participant categorization
Back to Top